These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16697875)

  • 41. Treatment of muscle-invasive bladder cancer.
    Sherif A; Jonsson MN; Wiklund NP
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1279-83. PubMed ID: 17892428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bladder cancer--contemporary dilemmas in its management.
    Whelan P
    Eur Urol; 2008 Jan; 53(1):24-6. PubMed ID: 17889428
    [No Abstract]   [Full Text] [Related]  

  • 43. Bladder cancer today.
    Sternberg CN; Lerner SP; Fitzpatrick JM
    BJU Int; 2008 Nov; 102(9 Pt B):1203. PubMed ID: 19035882
    [No Abstract]   [Full Text] [Related]  

  • 44. Assessment and management of deeply invasive and metastatic lesions.
    Whitmore WF
    Cancer Res; 1977 Aug; 37(8 Pt 2):2756-8. PubMed ID: 872102
    [No Abstract]   [Full Text] [Related]  

  • 45. Bladder cancer imaging.
    Legg JS
    Radiol Technol; 2008; 79(4):333-46; quiz 347-9. PubMed ID: 18340023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
    Azuma H; Yamamoto K; Inamoto T; Ibuki N; Kotake Y; Sakamoto T; Kiyama S; Ubai T; Takahara K; Segawa N; Narumi Y; Katsuoka Y
    Am J Clin Oncol; 2009 Dec; 32(6):592-606. PubMed ID: 19593084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What is the significance of pT0 at cystectomy?
    Hotston M; Patel S; Sohail M; Persad RA
    Surg Oncol; 2006 Aug; 15(2):65-9. PubMed ID: 16971115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Herr HW
    Eur Urol; 2008 Jul; 54(1):126-32. PubMed ID: 18248875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
    Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
    Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical significance of pelvic lymph-node dissection for the patients with locally invasive bladder cancer--correlation between the number of retrieved lymph nodes and prognosis].
    Noguchi S; Takase K; Oogo Y; Muraoka K; Shioi K; Nakamura M; Onuki T; Kishi H; Satomi Y; Fukuda M
    Hinyokika Kiyo; 2006 May; 52(5):327-30. PubMed ID: 16758719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The curability of vesical cancer: greater now or then?
    Marshall VF; McCarron JP
    Cancer Res; 1977 Aug; 37(8 Pt 2):2753-5. PubMed ID: 872101
    [No Abstract]   [Full Text] [Related]  

  • 53. The optimal management of T1G3 bladder cancer.
    Emiliozzi P; Pansadoro A; Pansadoro V
    BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
    [No Abstract]   [Full Text] [Related]  

  • 54. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
    Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
    BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cancer of the urinary bladder: prognosis of the outcome].
    Zimichev AA; Prianichnikova MB; Maklakov VN
    Urologiia; 2009; (3):52-3. PubMed ID: 19673123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
    Izawa JI; Chin JL; Winquist E
    Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate.
    Ferreira U; Matheus WE; Nardi Pedro R; Levi D'Ancona CA; Reis LO; Stopiglia RM; Denardi F; Rodrigues Netto N; de Cássio Zequi S; da Fonseca FP; Lopes A; Cardoso Guimarães G; de Carvalho Fernandes R; Cardenuto Perez MD
    Urol Int; 2007; 79(3):200-3. PubMed ID: 17940350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bladder cancer: improving care with better classification and risk stratification.
    Lamm D
    J Urol; 2007 Oct; 178(4 Pt 1):1146-7. PubMed ID: 17698132
    [No Abstract]   [Full Text] [Related]  

  • 59. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?
    Liedberg F; Anderson H; Chebil G; Gudjonsson S; Höglund M; Lindgren D; Lundberg LM; Lövgren K; Fernö M; Månsson W
    Urol Oncol; 2008; 26(1):17-24. PubMed ID: 18190825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
    Raj GV; Herr H; Serio AM; Donat SM; Bochner BH; Vickers AJ; Dalbagni G
    J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.